De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Teva Pharmaceutical Industries Balans Gezondheid
Financiële gezondheid criteriumcontroles 2/6
Teva Pharmaceutical Industries heeft een totaal eigen vermogen van $6.6B en een totale schuld van $18.6B, wat de schuld-eigenvermogensverhouding op 284% brengt. De totale activa en totale passiva bedragen respectievelijk $41.3B en $34.8B. De EBIT Teva Pharmaceutical Industries is $3.5B waardoor de rentedekking 3.6 is. Het heeft contanten en kortetermijnbeleggingen van $2.3B.
Belangrijke informatie
284.0%
Verhouding schuld/eigen vermogen
US$18.64b
Schuld
| Rente dekkingsratio | 3.6x |
| Contant | US$2.26b |
| Aandelen | US$6.56b |
| Totaal verplichtingen | US$34.78b |
| Totaal activa | US$41.34b |
Recente financiële gezondheidsupdates
Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?
Jul 12
Teva Pharmaceutical Industries (NYSE:TEVA) Has A Somewhat Strained Balance Sheet
Mar 26These 4 Measures Indicate That Teva Pharmaceutical Industries (NYSE:TEVA) Is Using Debt In A Risky Way
Dec 11Teva Pharmaceutical Industries (NYSE:TEVA) Has No Shortage Of Debt
Sep 09Here's Why Teva Pharmaceutical Industries (NYSE:TEVA) Is Weighed Down By Its Debt Load
Jun 06Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?
Feb 20Recent updates
Cheap Teva Stock Should Reward Patient Investors
Sep 09Teva's Transformation: From Generics Leader To Branded Drug Innovator
Aug 14Teva Pharmaceutical Industries Limited (NYSE:TEVA) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 02Teva's Q2 Outlook: Key Developments In Biosimilars And Pipeline Drugs
Jul 26Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?
Jul 12Teva Pharmaceutical: Buy This Bargain Before It's Gone
Jun 07Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
May 14Teva: Sustained Revenue Growth Amid Financial Strain (Rating Downgrade)
May 09Teva Pharmaceutical Industries (NYSE:TEVA) Has A Somewhat Strained Balance Sheet
Mar 26Teva Pharmaceutical Industries: Potential Outweighs Concerns
Mar 25Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities
Feb 26A Review Of Teva's Prospects
Feb 15Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Business And Shares Still Trailing The Industry
Jan 07These 4 Measures Indicate That Teva Pharmaceutical Industries (NYSE:TEVA) Is Using Debt In A Risky Way
Dec 11Teva: 4 Key Drivers For A 2024 Revival (Upgraded Rating)
Dec 08Teva: Deeply Undervalued FCF Machine
Nov 20Teva: Focus On Innovation And Growth Means The Times They Are A Changing
Sep 14Teva Pharmaceutical Industries (NYSE:TEVA) Has No Shortage Of Debt
Sep 09The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider
Aug 26Teva Q2 Earnings: Austedo And Anda Growth Impress, But Challenges Remain
Aug 02Teva Pharmaceutical: Lacking Capabilities For Strategic Investments
Jul 20Teva Pharmaceutical: New Growth Plan Could Restore Investor Confidence
Jun 15Here's Why Teva Pharmaceutical Industries (NYSE:TEVA) Is Weighed Down By Its Debt Load
Jun 06Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?
Feb 20What To Expect From Teva Pharmaceutical In 2023 With A New CEO
Feb 15Can Teva Pharmaceutical's Q4 results bring positive surprise?
Feb 07Teva Pharmaceutical: Stuck In A Cycle Of Hope And Disappointment
Jan 19Tamiflu supplies released from national stockpile as nationwide shortage persists
Jan 12Teva Pharmaceutical: 2023 Could Finally Be The Stock's Breakout Year
Dec 28Federal appeals court temporarily blocks generics of Vanda's Hetlioz by Teva, Apotex
Dec 16Boston jury orders Lilly to pay $176.5M to Teva in migraine drug patent suit
Nov 10Teva Pharmaceutical to pay New York $523M as part of opioid settlement
Nov 03Teva data indicates long-term benefit of Austedo for chorea associated with Huntington's
Oct 18Novartis division Sandoz reports supply issue of generic ADHD drug Adderall - Bloomberg
Oct 06Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( $11.6B ) van TEVA } dekken niet de korte termijn passiva ( $13.0B ).
Langlopende schulden: De kortetermijnactiva van TEVA ( $11.6B ) dekken de langetermijnschulden ( $21.7B ) niet.
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: De netto schuld/eigen vermogen ratio ( 249.6% ) TEVA wordt als hoog beschouwd.
Schuld verminderen: De schuld/eigen vermogen-ratio van TEVA is de afgelopen 5 jaar gestegen van 188.4% naar 284%.
Balans
Analyse van de cashflow
Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.
Stabiele cash runway: Terwijl het verlieslatende TEVA voldoende cash runway heeft voor meer dan 3 jaar, als het zijn huidige positieve vrije kasstroom-niveau behoudt.
Voorspelling contante baan: TEVA is verlieslatend, maar heeft voldoende kasmiddelen voor meer dan 3 jaar, zelfs bij een positieve vrije kasstroom die met 11.4 % per jaar krimpt.